News GSK plc

Equities

Market Closed - London S.E. Other stock markets 11:35:04 2024-05-31 am EDT			5-day change	1st Jan Change
1,766 ^GBX	+2.11%		-0.45%	+21.81%

Jun. 01	Delaware judge lets more than 70,000 Zantac lawsuits go forward	RE
Jun. 01	GSK Regarding Ruling By Delaware State Court On Zantac Litigation Will Immediately Seek Appeal	RE

Delaware judge lets more than 70,000 Zantac lawsuits go forward	Jun. 01	RE
GSK Regarding Ruling By Delaware State Court On Zantac Litigation Will Immediately Seek Appeal	Jun. 01	RE
US FDA approves Moderna's RSV vaccine, its second marketed product	May. 31	RE
Goldman Sachs Starts GSK With Neutral Rating, $47 Price Target	May. 30	MT
Goldman Sachs Initiates GlaxoSmithKline with Neutral Rating	May. 30	MT
Jefferies and UBS cut Anglo American	May. 30	AN
Dr Martens cuts payout as profit plummets	May. 30	AN
GSK : Upgraded to Neutral by Goldman Sachs	May. 30	ZD
US nears deal to fund Moderna's bird flu vaccine trial, FT reports	May. 30	RE
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	May. 29	MT
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	May. 29	AQ
CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	May. 28	MT
US, European nations consider vaccinating workers exposed to bird flu	May. 27	RE
British Stocks Extend Losing Streak Amid Retail Sales Slump	May. 24	MT
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases - Form 6-K	May. 24	PU
Rate outlook weighs on equities	May. 24
GSK: successful verdict in Zantac case	May. 24	CF
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	May. 24	AQ
GSK: to present its advances in oncology at ASCO	May. 24	CF
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases \| GSK	May. 24	AQ

No results for this search

GSK plc : Back on track

May 03, 2024 at 05:17 am EDT

GSK PLC : Encouraging start to 2024; guidance raised